Rallybio CorpNASDAQ:RLYB
- LAST PRICE1.0200
- TODAY'S CHANGE (%)0.0314 (3.1762%)
- Bid / Lots1.0200/ 11
- Ask / Lots1.0800/ 50
- Open / Previous Close1.0000 / 0.9886
- Day Range
- 52 Week Range
- Volume65,109
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RLYB |
|---|---|---|
| 09:32 ET | 1538 | 1 |
| 09:35 ET | 345 | 0.9886 |
| 09:50 ET | 200 | 1.03 |
| 09:55 ET | 200 | 1.03 |
| 10:04 ET | 100 | 1.04 |
| 10:06 ET | 200 | 1.015 |
| 10:11 ET | 100 | 1.04 |
| 10:15 ET | 3173 | 1.015 |
| 10:22 ET | 1216 | 1.04 |
| 10:26 ET | 110 | 1.03 |
| 10:27 ET | 300 | 1.03 |
| 10:29 ET | 375 | 1.03 |
| 10:31 ET | 842 | 1.0494 |
| 10:45 ET | 300 | 1.0284 |
| 11:02 ET | 100 | 1.02 |
| 11:05 ET | 311 | 1.0199 |
| 11:14 ET | 272 | 1.02 |
| 11:20 ET | 100 | 1.01 |
| 11:36 ET | 100 | 1.03 |
| 11:45 ET | 500 | 1.02 |
| 11:48 ET | 100 | 1.03 |
| 11:59 ET | 150 | 1.03 |
| 12:14 ET | 100 | 1.03 |
| 12:28 ET | 100 | 1.03 |
| 12:48 ET | 100 | 1.03 |
| 12:53 ET | 200 | 1.03 |
| 01:13 ET | 381 | 1.03 |
| 01:20 ET | 100 | 1.02 |
| 01:22 ET | 655 | 1.03 |
| 01:27 ET | 1000 | 1.025 |
| 01:31 ET | 110 | 1.04 |
| 01:33 ET | 110 | 1.04 |
| 01:38 ET | 100 | 1.04 |
| 01:47 ET | 2291 | 1.02 |
| 01:51 ET | 370 | 1.02 |
| 02:00 ET | 120 | 1.0123 |
| 02:18 ET | 10072 | 1.03 |
| 02:20 ET | 100 | 1.03 |
| 02:23 ET | 915 | 1.01 |
| 02:32 ET | 3000 | 1.02 |
| 02:38 ET | 567 | 1.02 |
| 02:52 ET | 1533 | 1.025 |
| 03:03 ET | 18377 | 1.0599 |
| 03:10 ET | 428 | 1.1 |
| 03:19 ET | 811 | 1.0866 |
| 03:28 ET | 100 | 1.08 |
| 03:30 ET | 400 | 1.06 |
| 03:37 ET | 410 | 1.0606 |
| 03:50 ET | 100 | 1.05 |
| 03:53 ET | 254 | 1.05 |
| 03:55 ET | 400 | 1.06 |
| 03:57 ET | 153 | 1.06 |
| 04:00 ET | 4249 | 1.02 |
Yesterday
Nov 21, 2024
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212, from 8:00AM ET on Thursday Nov 21, 2024 by Dow Jones
8:00AM ET on Thursday Nov 21, 2024 by Dow Jones
Nov 8, 2024
DJ Rallybio Is Maintained at Buy by HC Wainwright & Co., from 2:23PM ET on Friday Nov 08, 2024 by Dow Jones
2:23PM ET on Friday Nov 08, 2024 by Dow Jones
Nov 7, 2024
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates, from 8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
8:00AM ET on Thursday Nov 07, 2024 by Dow JonesPress Release: Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates, from 8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Rallybio Corp | 42.3M | -0.6x | --- |
vTv Therapeutics Inc | 42.7M | -3.2x | --- |
Iterum Therapeutics PLC | 41.1M | -0.9x | --- |
Achilles Therapeutics PLC | 43.6M | -0.6x | --- |
AN2 Therapeutics Inc | 40.0M | -0.7x | --- |
Exicure Inc | 39.9M | -8.1x | --- |
Company Information
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. It has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, RLYB331 and ENPP1 Program. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule with PK properties designed for the treatment of complement-mediated ophthalmic diseases. RLYB331 is for the treatment of severe anemia.
Contact Information
- Headquarters
- 234 CHURCH STREET, SUITE 1020NEW HAVEN, CT, United States 06510
- Phone
- 203-859-3820
- Fax
- 302-636-5454
Executives
- Executive Chairman of the Board
- Martin Mackay
- President, Chief Executive Officer, Director
- Stephen Uden
- Chief Financial Officer, Treasurer
- Jonathan Lieber
- Chief Medical Officer
- Steven Ryder
- Independent Director
- Helen Boudreau
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $42.3M |
|---|---|
Revenue (TTM) | $598.0K |
Shares Outstanding | 41.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.64 |
EPS | $-1.59 |
Book Value | $2.81 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 70.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -12,110.70% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
